Patents by Inventor Jun Shinga

Jun Shinga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified immunocyte, method for producing modified immunocyte and utilization thereof
    Patent number: 11834674
    Abstract: A modified immunocyte: (1) which expresses an exogenous unmodified T cell receptor ?-chain and an exogenous T cell receptor ?-chain on the cell surface thereof; or (2) which contains a polynucleotide encoding a T cell receptor ?-chain and a polynucleotide encoding a T cell receptor ?-chain. Thus, a new tool whereby immunity can be appropriately induced in vivo is provided.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: December 5, 2023
    Assignee: RIKEN
    Inventors: Shin-ichiro Fujii, Kanako Shimizu, Satoru Yamasaki, Jun Shinga
  • MODIFIED IMMUNOCYTE, METHOD FOR PRODUCING MODIFIED IMMUNOCYTE AND UTILIZATION THEREOF
    Publication number: 20180044631
    Abstract: A modified immunocyte: (1) which expresses an exogenous unmodified T cell receptor ?-chain and an exogenous T cell receptor ?-chain on the cell surface thereof; or (2) which contains a polynucleotide encoding a T cell receptor ?-chain and a polynucleotide encoding a T cell receptor ?-chain. Thus, a new tool whereby immunity can be appropriately induced in vivo is provided.
    Type: Application
    Filed: December 11, 2015
    Publication date: February 15, 2018
    Inventors: Shin-ichiro FUJII, Kanako SHIMIZU, Satoru YAMASAKI, Jun SHINGA
  • Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
    Patent number: 9783821
    Abstract: A cell of the present invention contains a nucleic acid construct encoding a WT1 gene product or a fragment of the WT1 gene product. The nucleic acid construct contains (i) a region encoding a desired fragment of the WT1 gene product and (ii) only AUG as a functional start codon. The present invention can provide a cell into which the nucleic acid construct is introduced so that an expression level of a WT1 gene product or a fragment of the WT1 gene product is remarkably enhanced.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: October 10, 2017
    Assignee: RIKEN
    Inventors: Shin-ichiro Fujii, Kanako Shimizu, Jun Shinga
  • CELL FOR USE IN IMMUNOTHERAPY WHICH CONTAINS MODIFIED NUCLEIC ACID CONSTRUCT ENCODING WILMS TUMOR GENE PRODUCT OR FRAGMENT THEREOF, METHOD FOR PRODUCING SAID CELL, AND SAID NUCLEIC ACID CONSTRUCT
    Publication number: 20140179004
    Abstract: A cell of the present invention contains a nucleic acid construct encoding a WT1 gene product or a fragment of the WT1 gene product. The nucleic acid construct contains (i) a region encoding a desired fragment of the WT1 gene product and (ii) only AUG as a functional start codon. The present invention can provide a cell into which the nucleic acid construct is introduced so that an expression level of a WT1 gene product or a fragment of the WT1 gene product is remarkably enhanced.
    Type: Application
    Filed: July 30, 2012
    Publication date: June 26, 2014
    Applicant: RIKEN
    Inventors: Shin-ichiro Fujii, Kanako Shimizu, Jun Shinga